Guangzhou Continent Biomedical

Guangzhou Continent Biomedical is a clinical-stage biotechnology company based in China, primarily focused on the development and commercialization of innovative therapies for organ fibrosis. The company is a key subsidiary of Beijing Continent Pharmaceutical (part of the Gyre Pharmaceuticals group) and serves as a strategic hub for research and development in Southern China. Its core focus revolves around pirfenidone-based derivatives and other small molecules targeting transforming growth factor-beta (TGF-β) and platelet-derived growth factor (PDGF) pathways. The company's lead programs aim to address significant unmet needs in idiopathic pulmonary fibrosis, kidney fibrosis, and liver cirrhosis.